Onconetix: Funding, Investors & Team (Sep 2026)
Blue Water Biotech Inc. (Nasdaq: BWV) is a biopharmaceutical company focused on developing transformational therapies to address significant health challenges globally. The company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.
Onconetix has raised $28.1M across 2 funding rounds on record, the most recent an undisclosed round of $27.0M announced in Oct 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Onconetix Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Onconetix Funding Rounds
Onconetix raised $1.1M in an undisclosed round announced in Jul 2024.
3 months later, an undisclosed round of $27.0M was announced in Oct 2024.
Onconetix Founders and Leadership Team
No contact details are on record for this team yet.
Onconetix Funding Compared to Other Biotechnology Startups
Onconetix's latest round of $27.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Onconetix in Biotechnology and Cincinnati
Companies Similar to Onconetix
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Onconetix Funding FAQs
What does Onconetix do?
Blue Water Biotech Inc. (Nasdaq: BWV) is a biopharmaceutical company focused on developing transformational therapies to address significant health challenges globally. The company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.
How much funding has Onconetix raised?
Onconetix has raised $28.1M across 2 rounds on record. The most recent is an undisclosed round of $27.0M announced in Oct 2024.
When did Onconetix last raise funding?
Onconetix's most recent funding round on record is an undisclosed round of $27.0M, announced in Oct 2024.
Who founded Onconetix?
FundedIQ lists Joseph Hernandez (Founder) at Onconetix.
Where is Onconetix headquartered?
Onconetix is based in Cincinnati, Ohio, United States.
How many employees does Onconetix have?
Onconetix is in the 11-50 employee band.
How does Onconetix's funding compare to other Biotechnology startups?
Onconetix's latest round of $27.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Onconetix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Onconetix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.